- Home
- ACLX vs GBDC Comparison
ACLX vs GBDC Comparison
Compare ACLX & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACLX | GBDC |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 2022 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ACLX | GBDC |
|---|---|---|
| Price | $114.51 | $12.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 3 |
| Target Price | ★ $115.85 | $14.17 |
| AVG Volume (30 Days) | 2.3M | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 12.53% |
| EPS Growth | N/A | ★ 4.41 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $22,286,000.00 | N/A |
| Revenue This Year | $397.53 | N/A |
| Revenue Next Year | $123.06 | N/A |
| P/E Ratio | ★ N/A | $49.90 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.86 | $11.77 |
| 52 Week High | $114.91 | $15.63 |
Technical Indicators
Market Signals| Indicator | ACLX | GBDC |
|---|---|---|
| Relative Strength Index (RSI) | 81.32 | 51.22 |
| Support Level | $66.06 | $12.28 |
| Resistance Level | $114.80 | $12.67 |
| Average True Range (ATR) | 0.30 | 0.25 |
| MACD | -1.62 | 0.07 |
| Stochastic Oscillator | 41.18 | 74.55 |
Price Performance
Historical ComparisonAbout ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.